News & Trends - MedTech & Diagnostics
Coloplast to maintain interventional urology business
Coloplast will keep the company’s interventional urology business — about five months after confirming it was the subject of a strategic review.
“After completing a thorough review, we have firmly concluded that the interventional urology business is core to our mission, and that retaining the business is the right decision to deliver continued shareholder value creation. Fundamentally, we observe large, fast-growing markets and real unmet clinical needs representing long-term growth opportunities,” CEO Kristian Villumsen said in a news release today.
“Today, the business delivers strong growth and profitability, which is a good outset from which to invest and develop the business further, to derive even greater long-term value,” Villumsen said.
The division enjoyed 10% organic growth during the fiscal year ended Sept. 30, more than any other division in the company. But there were also apparently concerns. The strategic review announcement in June came about two months after the U.S. FDA ordered Coloplast and Boston Scientific— the only two companies still selling surgical mesh for transvaginal repair of pelvic organ prolapse — to stop selling the devices. Transvaginal mesh came under scathing criticism last year from reports including the International Consortium of Investigative Journalists’ Implant Files.
Coloplast is setting aside the equivalent of more than $60 million to cover potential settlements in vaginal mesh cases.
You may also like Where credibility and trust go, clinicians follow. Download whitepaper.
Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.
News & Trends - MedTech & Diagnostics
AI-assisted colonoscopy boosts polyp and adenoma detection
MedTech & Diagnostics News: In a standard colonoscopy, as many as one-third of colorectal polyps and adenomas can go by […]
MoreNews & Trends - Pharmaceuticals
‘Every day of delay is costing Australian lives’, says Rare Cancers Australia CEO
Pharma News: Rare Cancers Australia (RCA) has voiced its disappointment alongside the pharmaceutical industry following the Pharmaceutical Benefits Advisory Committee’s […]
MoreNews & Trends - Pharmaceuticals
Government’s silence on Senate report leaves cancer patients in limbo
Pharma News: NeuroEndocrine Cancer Australia has urged the government to respond to the Senate report on equitable access to diagnosis […]
More